

**Rational Polypharmacy in Pain Management** 

Charles Argoff, MD

1

#### Disclosures

Charles E. Argoff, MD Professor of Neurology, Albany Medical College; Director, Comprehensive Pain Center Albany Medical Center

Consultant/Independent Contractor: Prizer, Lilly, Regeneron, Teva, US World Meds, Collegium, kaléo, Quest, Vertex, Novartis Grant/Research Support: Vertex, Grünenthal Honoraria: Allergan, BDSI, DSI, AZ, Amgen, Teva, Novartis Stock Shareholder: Pfizer, Depomed Other/Royatty: Elsevier, Cambridge Press

#### Drug/Product Off-Label Use

Off-label use of a drug and/or product will be addressed in this presentation
 This information will be verbally disclosed both at the beginning of the presentation and at the time of drug/product discussion

Painweek.

2

#### Learning Objectives

Define rational polypharmacy and when it is indicated for pain management

- List the array of medications and their MOAs that may be employed in polypharmacy
- Discuss the pharmacologic and clinical considerations of which the prescriber should be aware

• Explain painful conditions where polypharmacy might be considered

## **Real Patients to Consider in Our Discussion**

- •60 year old male experiencing painful diabetic neuropathy and chronic LBP
- •50 year old female who experiences fibromyalgia and migraine
- 70 year old female who experiences osteoporosis, osteoarthritis, and
- postherpetic neuralgia
- 52 year old male who experiences post-laminectomy pain
- 28 year old female with chronic migraine

# Painweek.

4

#### Selecting an Analgesic: Evidence and Guideline Limitations

- · Paucity of trials on comparative effectiveness of different treatments
- Most treatment trials are of short duration with limited evidence for functional benefit
- Few trials evaluate strategies for choosing initial agent
- Various clinical practice guidelines may interpret evidence differently
- Clinical practice guidelines may not include latest evidence
   -Duloxetine for low back pain or osteoarthritis

Painweek.

Chappell AS, et al. Pain. 2009;146:253:260; Chappell AS, et al. Pain Pract. 2011;11:33-41; Kroenke K, et al. Gen Hoop Papulatiny. 2008;31:2062;19; Skijamveki V, et al. Pain Med. 2010;11:648-657; Skijamveki V, et al. J Pain. 2010;11:1224:265; Skijamveki V, et al. Spine (Phila Pa 1976). 2010;35:E578-565; Walace M, et al. Expert Rev Neurother. 2011;11:15:27.

5

#### What Is Polypharmacy?

Defined as

- -Intentional use of 2 or more medications to treat 1 condition
- Example: opioids + NSAIDs to treat low back pain, OR
   Use of 2 or more medications by 1 patient to treat multiple conditions
- Example: antihypertensives, antidepressants, NSAIDs, and statins, OR
- -Use of 2 or more agents of the same chemical class
- Polypharmacy should be minimized whenever possible; however, it may be warranted under certain circumstances

# **Rational Polypharmacy**

# Rational polypharmacy May help reduce chronic pain

-Reduction of chronic pain can improve patient outcomes

# Painweek.

7

# Rational Polypharmacy (cont'd)

Rational polypharmacy has become an acceptable component of chronic pain management

-More therapeutic options are being made available

Useful to target pain that has peripheral and central mechanisms

• Consider the following when selecting combined regimens: -Side effects (SEs)

-Medication interactions

-Ease of use

-Costs

#### Painweek.

8

#### Why Is Rational Polypharmacy Used?

Patients with pain

-May experience only a partial response to monotherapy

-Cannot tolerate adverse events at analgesic doses of monotherapy -May have positive synergistic effects with combined agents from different medication classes

#### Painweek.

# Multidrug Therapy Proposed Principles for Chronic Pain

- Purpose is to combine medications to achieve additive or synergistic analgesia
   -Potentially at lower doses (and fewer side effects) than those required with monotherapy
- Combine medications with differing mechanisms or sites of action, based on patient response, functional goals, clinical experience, and potential adverse interactions
- Consider interactions of newly added drug with current medications Select and use one drug at a time
- Start low, go slow for dosing and titration, particularly in older patients
- Ongoing reassessment is critical
- -Assess for clinically meaningful relief and document functional outcomes
- Painweek, Backonja MM, et al. Curr Pain Headache Rep. 2006;10:34-38; Gilron I, et al. Lancet. 2009;374:1252-1261.

10

#### The Chronic Pain PHARMACOLOGIC Armamentarium

Nonopioids

- -Acetaminophen
- -NSAIDs -COX-2 inhibitors
- -Antidepressants
- Anticonvulsants
   Topical agents, other

Opioids

-Mu-opioid agonist -Partial agonists

Painweek.

11

Chemical Class/Examples	Class Examples	Brands/Examples
ara-aminophenols	Acetaminophen	Tylenol®
ialicylates	Aspirin Choline magnesium trisalicylate (CMT) Choline salicylate Magnesium salicylate Diflunisal	Bayer® Bufferin® Trilisate® Arthropan® Doan's® Argesic® Salgesic® Dolobid®
* Not an exhaustive list of class/examples.		

Chemical Class	Class Examples	Brands	
Arylpropionic/propionic	Ibuprofen	Advil®	
derivatives	Naproxen Ketoprofen Flurbiprofen	Motrin® Aleve® Anaprox®	
	Fenoprofen Oxaprozin	Naprelan® Naprosyn®	
		Orudis® Oruvail® Ansaid®	
		Nalfon® Daypro®	
Indole and indene acetic acids	Indomethacin	Indocin® Indocin® SR	

# 13

# **Clinical Indications: Nonopioids**

- Variety of acute and chronic pain types –Eg, trauma, post-op, cancer, arthritis
- Somatic pain
- -Muscle and joint pain, bone/dental pain, inflammatory pain, post-op pain
- APAP vs NSAIDs
- Acetaminophen has analgesic, antipyretic effects
   But lacks anti-inflammatory effect
   -NSAIDs have analgesic, anti-inflammatory, and antipyretic effects But affect gastric mucosa, platelets

# Painweek.


14

#### **Clinical Indications: Opioids**

- Moderate-severe pain unresponsive to nonopioids alone
- -Example: acute pain

- -Example. actice pain Post-op, trauma -Breakthrough pain -Cancer pain -Chronic, noncancer pain

## Painweek.



16

# Adjuvant Analgesics: **Tricyclic Antidepressants**

#### Examples

- -TCAs include amitriptyline, desipramine, doxepin, imipramine, nortriptyline •MOA -Inhibition of reuptake of norepinephrine and serotonin -Analgesia is independent of antidepressant function Uses
  - -Chronic pain examples: migraine, other headaches, low back pain, cancer pain, fibromyalgia -Neuropathic pain examples: PDN, PHN, cancer-related pain
- -Common adverse events (AEs) Examples: sedation, orthostatic hypotension and anticholinergic effects (ie, dry mouth, blurred vision, constipation, urinary retention)

# Painweek.



#### **Adjuvant Analgesics:** Selective Serotonin Reuptake Inhibitors

#### Examples

- -SSRIs include citalopram, paroxetine, fluoxetine, sertraline • MOA
- -Selectively inhibit 5-HT reuptake without affecting norepinephrine Uses
- -Examples: neuropathic pain, diabetic neuropathy
- Common AEs
- -Examples: anxiety, insomnia, nausea, headache, drowsiness, sexual dysfunction, withdrawal symptoms upon abrupt cessation




# Adjuvant Analgesics: Serotonin/Norepinephrine Reuptake Inhibitors

- Examples -SNRIs include duloxetine and venlafaxine MOA -Block reuptake of 5-HT and norepinephrine
- Uses
- -Example: diabetic peripheral neuropathy (DPN)
- Common AEs -Examples: nausea, somnolence, dizziness, constipation, dry mouth, hyperhidrosis, anorexia

Painweek.

19



20

# **Adjuvant Analgesics: Anticonvulsants** Examples AEDs include gabapentin, pregabalin, carbamazepine, phenytoin, divalproex sodium, clonazepam, levetiracetam, topiramate, lamotrigine MOA: exact mechanism of analgesic effect is unknown; it is thought they - Reduce membrane excitability - Suppress abnormal discharges in pathologically altered neurons Uses -Neuropathic pain (PDN, PHN, RSD, PSP, TN) -Cancer pain, HIV-related neuropathy, phantom limb pain -Migraine (prophylaxis), dysesthesia, deafferentation pain, thalamic pain Common AEs -Sedation, headache, dizziness, rash, vertigo, ataxia, nausea, diplopia

# **Adjuvant Analgesics: Topicals**

#### Examples

- -Lidocaine, Lidoderm, EMLA®, Capsaicin cream
- MOA -Lidocaine/prilocaine: block sodium channels and inhibit generation of abnormal -Capsaicin: depletion of substance P in sensory nerve endings
- Uses
- --Examples in acute and chronic pain
   •PHN, other neuropathic pain, mechanical allodynia
   •Pain associated with medical procedures: needle insertion, cannulation, epidural nerve blocks
- Common AEs
  - -Examples: localized reaction including burning sensation

#### Painweek.

22

#### The Potential Benefits of Rational Polypharmacy

- Enhance current treatment
- Use a lower dose of a medication
- Target symptom clusters (eg, pain and depression)
- Ease the treatment of a comorbid condition
- (eg, control diabetes to reduce DPNP)
- Address different pain mechanisms (eg, central and peripheral mechanisms)
- Treat AEs

#### Painweek.

23

#### **Considerations for Rational Polypharmacy**

Know medication toxicities

- Avoid overlapping/additive toxicities
- Know medication MOAs
- Know medication PK/PD
- -Avoid drug-drug interactions
- · Have convincing evidence that the combination is more effective vs monotherapy and should not pose significantly greater safety or tolerability risks

# **MOA Considerations for Polypharmacy**

- When using multiple medications, consider carefully the MOA of each drug: Each drug should have one MOA
   Drugs should not have broad-acting MOA
   Drugs should not have the same MOA
  - -Drugs should not have opposing MOAs

# Painweek.

25

# **Possible Drug-Drug Interactions**

- Interaction of absorption: one drug may cause an increase/decrease in the absorption of the other in the GI system
- Interaction of protein binding
- Interaction of metabolism (eg, CYPs)
- Interaction of receptor binding
- Interaction of therapeutic action

#### Painweek.

26

# **Types of Drug-Drug Interactions**

Additive

- Synergistic
- Potentiation
- Antagonism
- -Functional/physiological

-Chemical/inactivation -Dispositional

-Receptor

#### Painweek.

# P450 Enzymes

Care should be taken when coadministering drugs whose metabolism might be inhibited by other drugs in order to prevent adverse drug reactions (ADRs)
 -For example, SSRIs inhibit the metabolism of drugs mediated by certain P450 enzymes
 > 30 human CYP isoenzymes have been identified
 ≥ 90% of drug oxidation can be attributed to 6 main P450 cytochromes:
 -1A2
 -2C9
 -2C19
 -2D6
 -2E1
 -3A4

Painweek.

28

#### **Phases of Medication Metabolism**

Phase I: oxidation/reduction/hydrolysis

 Oxidation to the parent compound or deletion of the alkyl group, reduction, and hydrolysis reactions

Phase II: conjugation

-Biotransformation links a parent medication molecule or product of Phase I metabolism with an endogenous substrate (eg, glucuronic acid, sulfate, or glycine)

# Painweek.

29

#### Induction and Inhibition

Induction

-Increase of enzyme metabolism by a medication

-Increasing doses are needed to produce same effect, as the body metabolizes the drug more quickly

Inhibition

-Decreased enzyme activity due to direct interaction with a medication or chemical -Doses should be decreased due to a decrease in metabolism

# When Is Polypharmacy Indicated in Pain Management?

- To reduce medication intolerance by using a second medication that allows a lower dose of the first
   -May increase treatment compliance
- To provide analysis of efficacy at certain times of the day by giving immediaterelease with long-acting medications
- -Example: control breakthrough pain in a patient taking long-acting opioids

# Painweek.

31

# When Is Polypharmacy Indicated in Pain Management? (cont'd)

- To use a lower dose of a medication by using a second medication -Example: opioid-sparing
- To address partial or nonresponse to 1 medication by adding a second medication to increase efficacy

   Example: using 2 different antidepressants with different MOAs

#### Painweek.

32

#### When Is Polypharmacy Indicated in Pain Management? (cont'd)

- To target different symptom clusters that are a product of the disease or of the comorbid disease
- -Example: pain with associated depression, which in turn is associated with suicidal ideation
- -Example: treat diabetes aggressively, thereby reducing the peripheral neuropathy severity

# When Is Polypharmacy Indicated in Pain Management? (cont'd)

- To address different locations of the disease process

   Example: pain with peripheral AND central mechanisms that require medications with
   peripheral and central activity

   Example: topical lidocaine patch with antidepressant
- To treat an adverse event

# Painweek.

34

# Checklist for Controlling Pain in a Polypharmacy Environment

Prescribers are charged with

-Prudent attention to the patient's past medication history, including OTC preparations -Vigilant surveillance of systemic function

-Pharmacologic alternatives when medications are inappropriate

#### Painweek.

35

#### 5 Principles of Polypharmacy for Pain Associated Comorbidity

• Use medications for comorbid disease with proven analgesic efficacy

- First target symptoms should ALWAYS be pain
- Target all possible pain mechanisms (eg, peripheral and central) believed to be causing the pain
- Do not aim for absolute pain relief
- -Aim for tolerable pain levels that improve QoL or function
- Use medications to address more than 1 comorbidity
   -Example: sedating antidepressant for pain, sleep, and depression

#### Summary of Implementing Rational Polypharmacy in the Treatment of Pain

 Polypharmacy, the use of multiple medications in a patient, should be minimized whenever possible; however, it may be warranted under certain circumstances

Rational polypharmacy may be employed when the benefits outweigh the risks

# Painweek.

37

# Summary of Implementing Rational Polypharmacy in the Treatment of Pain (cont'd)

- The benefits of rational polypharmacy include:
- -Enhancing current treatment -Using a lower dose of a medication
- -Targeting symptom clusters
- -Easing the treatment of a comorbid condition
- -Addressing different pain mechanisms -Treating AEs

#### Painweek.


38

#### Examples of "Rational" Polypharmacy in **Specific Pain Conditions**

Neuropathic pain

- Fibromyalgia
- Chronic headache
- Low back pain

#### Painweek.



40

#### Morphine, Gabapentin or their Combination for Neuropathic Pain

- Patients with postherpetic neuralgia or painful diabetic neuropathy
- Randomized, double-blind, active placebo-controlled, 4 period crossover trial
   Periods included active placebo (lorazepam), gabapentin, sustained release morphine, or a combination of both gabapentin and morphine each period 5 weeks
- Gabapentin and morphine combined achieved better analgesia at lower doses of each drug than either as a single agent

#### Painweek.

41

# Postherpetic Neuralgia: 5% Lidocaine Medicated Plaster, Pregabalin, or a Combination of Both?

Randomized, open label clinical effectiveness trial

- PHN patients with pain intensity score of greater than 4 were randomized to lidocaine plaster or pregabalin
- Patients experiencing pain intensity of 4 or less after 4 weeks remained on monotherapy

Those who did not received both medications after 4 weeks

Equal response between medications with monotherapy AND combining medications was well tolerated and improved response

# Combination of Morphine with Nortriptyline for Neuropathic Pain

- Combination compared to monotherapy of each in patients with neuropathic pain (1:1:1)
- •3 6-week treatment periods
- Superior efficacy noted with morphine-nortriptyline combination over either monotherapy
- Constipation, dry mouth, and somnolence most frequent adverse effects

#### Painweek.

43

#### Pregabalin with Duloxetine for Fibromyalgia

Randomized, double-blind 4 period crossover design
6 week periods

Placebo, pregabalin, duloxetine, or combination
Daily pain intensities improved most with combination

Fibromyalgia Impact Questionnaire scores improved most with combination

SF-36 scores improved most with combination

#### Painweek.

44

#### **MIGRAINE** Preventive Medications Anticonvulsants 5-HT antagonists – Divalproex\* – Gabapentin – Topiramate\* - Methysergide\*/methergine • Neurotoxins - Onabotulinum toxin A (Botox)\* Antidepressants Angiotensin system ACE inhibitors – TCAs, SSRIs, MAOIs • β-Blockers - Antagonists - Propranolol\*/Timolol\* Ca channel blockers Acetylcholinesterase inhibitors? Other – Verapamil Riboflavin, coenzyme Q10, Feverfew, Petasites NSAIDs FDA approvo-ACE, angiotensin cou-reuptake inhibitors; T Modi S, et al. Am Fan ~rstein SD, et al. ors; SSRI, s onverting enzyn TCA, tricyclic a colodi M, et al. Headache. 2002;42:596-602; 2006;731:72-78; 1 45 Painweek.

# Higraine Comorbid Conditions • Cardiovascular • Mood disorders - Heart attack/angina - Depression - Miral valve prolapse - Mania - Hypertension or hypotension - Anxiety - Stroke - Panic - Raynaud's syndrome - Stilberstein SD, et al. Cephalalgia. 2002;22:491-512

46

CNS	<ul> <li>GI disorders</li> </ul>
– Epilepsy	- Ulcer disease
– Essential tremo – Fibromyalgia	<ul> <li>Colitis</li> <li>Irritable bowel syndrome</li> </ul>
• All	ergy/Asthma
CNS, central nervous system; GI, gas	strointestinal. Silberstein SD, et al. Cephalalgia. 2002;22:491-512.
Week.	47

47

#### **Drug Treatment**

Assess coexisting conditions

- Do not treat migraine with drug contraindicated for other condition
- Do not use drug for other condition that exacerbates migraine

48

Beware of drug interactions

- Pay attention to women of childbearing potential
- Select 1 drug to treat both disorders?

Silberstein SD, et al. Headache. 2007;47:585-599.

# Comorbid and Coexisting Disorders Monotherapy?

Preferred, but may be exception rather than rule

 May not be best choice for either disorder
 β-blocker not first choice for hypertension
 Dose for one may not be adequate for second
 TCA migraine dose too low for depression

49

50

51

Silberstein SD, et al. *Headach*e. 2007;4740:585-599. Painweek.<sup>Silberstein SD, et al. *Headache*. 2007;4740:585-599</sup>

49

# Comorbid and Coexisting Disorders Monotherapy? (cont'd)

Therapeutic opportunities

- –Angina: β-blocker –Epilepsy: divalproex or topiramate
- Therapeutic limitations
- -Depression or asthma: avoid β-blockers
- -Epilepsy: caution with TCAs or neuroleptics

Silberstein SD, et al. Headache. 2007;4Silberstein SD, et al. Headache. 2007;4740:585-599. 740:585-599.

# Painweek.

50

# Comorbid and Coexisting Disease Therapeutic Independence

Silberstein SD, et al. Headache. 2007;4740:585-599.

# **Comorbid and Coexisting Disease** Therapeutic Independence (cont'd)

 Examples
 Depression: SSRI or SNRI plus AED (divalproex or topiramate) -Hypertension: ACE inhibitor or antagonists plus AED or TCA

ibitor; SSRI, selective se

52

53

54

# AED, antiepileptic drug; SNRI, serotonin-norepinephrine reuptake in Silberstein SD, et al. Headache. 2007;4740:585-599.

Painweek.

52

# **Comorbid and Coexisting Disease Depression**

• Migraine and depression comorbid

 TCAs often recommended for migraine -However, appropriate dose for depression often higher More adverse effects

## Silberstein SD, et al. Headache. 2007;4740:585-599.

Painweek.

53

# **Comorbid and Coexisting Disease Depression** (cont'd) Better approach -Treat depression with SSRI or SNRI and –Treat migraine with AED (divalproex or topiramate), $\beta$ -blocker, Ca channel blocker, or even low-dose TCA

Silberstein SD, et al. Headache. 2007;47:585-599.

#### Tizanidine and ibuprofen in acute low back pain

- Patients with acute low back pain randomized to receive either tizanidine 4 mg po 3 times daily with ibuprofen 400 mg 3 times daily or placebo plus ibuprofen 3 times daily
- Earlier improvement occurred in combination group, significantly better than ibuprofen alone by day 3
- More GI side effects noted with ibuprofen alone group supporting animal data that tizanidine can reduce GI side effects from NSAIDs

#### Painweek.

55

#### Conclusions

- Rational use of polypharmacy is indicated for pain management especially in specific painful conditions
- The prescriber should survey the array of medications and their MOAs that may be employed in polypharmacy
- Available studies suggest that rational approaches to polypharmacy in pain management can lead to improved analgesia and greater treatment tolerability

#### Painweek.

56

#### References

- Chappel AS et al Pain. 2009;146:253-260
- Chappel AS, et al.. Pain Pract 2011;11:33-41
- Kroenke K, et al. Gen Hosp Psychiatry 2009;31:206-219
- Skljarevski V, et al. Pain Med. 2010;11:648-657
- Skljarevski V et al. J Pain 2010;11:1282-1290.
- Skljarevski V et al. Spine (Phila PA 1976). 210;35:E578-585
  Wallace et al. Expert Rev Neurother 2011;11:15-27

#### Painweek.

# References (cont'd)

- Gilron I, et al. Lancet 2009;374:1252-1261
  Backonja MM, et al. Curr Pain Headache Rep 2006;10:34-38
- Silberstein SD et al. Neurology 2012; 78(17):1337-1345
- Gilron I et al. Pain 2015;156(8):1440-1448
- Gilron I et al. N Engl J Med 2005;352(13):1324-1334
- Gilron I et al.. Pain 2016;157(7): 1532-1540 Rehm S et al. Curr Med Res Opin 2010;26(7):1607-1619
- Berry H, Hutchinson DR. J Int Med Res 1988;16(2):83-91.

Painweek.